Ofatumumab treatment effect

Ofatumumab (Ofatumumab) is eliminated through target-independent pathways and B cell-mediated pathways, showing dose-dependent clearance in the dose range of 100 to 2000 mg. Due to B cell depletion, ofatumumab clearance was significantly decreased after subsequent infusions compared with the first infusion.

In a multicenter dose-escalation study including33 patients with relapsed or refractory chronic lymphocytic leukemia, most relevant adverse events occurred with the first infusion, and the number of adverse events decreased with each subsequent infusion, with 51% experiencing an infection and a response rate of 50%. One patient experienced a nodular partial response and 12 patients experienced a partial response. In summary, ofatumumab was well tolerated by patients with chronic lymphocytic leukemia (CLL) at doses up to 2000 mg.

Studies have shown that ofatumumab is effective in reducing the number of relapses and may also delay the progression of symptoms. In two major studies of 1,882 patients with relapsing forms of multiple sclerosis, patients treated with ofatumumab had an average of fewer than 0.11 relapses in a year, and fewer patients (8%) had symptom exacerbations lasting six months or longer than those taking teriflunomide (12%).

The original drug of ofatumumab has been launched in China and has also been included in medical insurance. Only patients who meet the indications can be reimbursed. The price is around tens of thousands of yuan, and domestic purchase channels are relatively difficult. The European version of ofatumumab original drug specifications20mg/0.4mL each sold overseas may cost around RMB 16,000 (the price may fluctuate due to the exchange rate). It is expensive and there are currently no generics of ofatumumab. For more drug information and specific prices, please consult a medical consultant.